207 related articles for article (PubMed ID: 27188752)
21. Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein.
Sakamoto Y; Shimizu T; Tobisawa S; Isozaki E
Neurol Sci; 2017 Dec; 38(12):2165-2169. PubMed ID: 28980134
[TBL] [Abstract][Full Text] [Related]
22. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies.
Nobile-Orazio E; Meucci N; Baldini L; Di Troia A; Scarlato G
Brain; 2000 Apr; 123 ( Pt 4)():710-7. PubMed ID: 10734002
[TBL] [Abstract][Full Text] [Related]
23. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.
Baron M; Lozeron P; Harel S; Bengoufa D; Vignon M; Asli B; Malphettes M; Parquet N; Brignier A; Fermand JP; Kubis N; Arnulf B
J Neurol; 2017 Jun; 264(6):1132-1135. PubMed ID: 28484839
[TBL] [Abstract][Full Text] [Related]
24. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
25. Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies.
Falzone YM; Campagnolo M; Bianco M; Dacci P; Martinelli D; Ruiz M; Bocci S; Cerri F; Quattrini A; Comi G; Benedetti L; Giannini F; Lauria G; Nobile-Orazio E; Briani C; Fazio R; Riva N
J Neurol; 2018 Dec; 265(12):2927-2933. PubMed ID: 30306264
[TBL] [Abstract][Full Text] [Related]
26. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
27. Multifocal motor neuropathy with high titers of anti-MAG antibodies.
Bridel C; Horvath J; Kurian M; Truffert A; Steck A; Lalive PH
J Peripher Nerv Syst; 2014 Jun; 19(2):180-2. PubMed ID: 24863375
[TBL] [Abstract][Full Text] [Related]
28. Differential diagnosis of chronic dysimmune demyelinating polyneuropathies with and without anti-MAG antibodies.
Isoardo G; Migliaretti G; Ciaramitaro P; Rota E; Poglio F; Tavella A; Paolasso I; Cavallo F; Bergamasco B; Cocito D
Muscle Nerve; 2005 Jan; 31(1):52-8. PubMed ID: 15536620
[TBL] [Abstract][Full Text] [Related]
29. Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide.
Eurelings M; Moons KG; Notermans NC; Sasker LD; De Jager AE; Wintzen AR; Wokke JH; Van den Berg LH
Neurology; 2001 Jan; 56(2):228-33. PubMed ID: 11160960
[TBL] [Abstract][Full Text] [Related]
30. Connecting impairment, disability, and handicap in immune mediated polyneuropathies.
Merkies IS; Schmitz PI; van der Meché FG; Samijn JP; van Doorn PA;
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):99-104. PubMed ID: 12486276
[TBL] [Abstract][Full Text] [Related]
31. IgM monoclonal gammopathy-associated neuropathies with different IgM specificity.
Matà S; Borsini W; Ambrosini S; Toscani L; Barilaro A; Piacentini S; Sorbi S; Lolli F
Eur J Neurol; 2011 Aug; 18(8):1067-73. PubMed ID: 21261794
[TBL] [Abstract][Full Text] [Related]
32. Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies.
Delmont E; Attarian S; Antoine JC; Paul S; Camdessanché JP; Grapperon AM; Brodovich A; Boucraut J
J Neurol; 2019 Aug; 266(8):1973-1979. PubMed ID: 31089861
[TBL] [Abstract][Full Text] [Related]
33. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings.
Vrethem M; Reiser N; Lauermann C; Svanborg E
Acta Neurol Scand; 2010 Jul; 122(1):52-7. PubMed ID: 20003083
[TBL] [Abstract][Full Text] [Related]
34. [Neuropathies associated with monoclonal IgM anti-MAG antibodies].
Pihan M; Decaux O; Marcorelles P; Bahon-Riedinger I; Lemercier S; Gainche-Salmon A; Doncker AV
Rev Med Interne; 2012 Dec; 33(12):686-92. PubMed ID: 22726239
[TBL] [Abstract][Full Text] [Related]
35. Binding specificity of anti-HNK-1 IgM M-protein in anti-MAG neuropathy: possible clinical relevance.
Hamada Y; Hirano M; Kuwahara M; Samukawa M; Takada K; Morise J; Yabuno K; Oka S; Kusunoki S
Neurosci Res; 2015 Feb; 91():63-8. PubMed ID: 25450311
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for IgM anti-Myelin-Associated Glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2003; (1):CD002827. PubMed ID: 12535440
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.
Vallat JM; Magy L; Ciron J; Corcia P; Le Masson G; Mathis S
Expert Rev Neurother; 2016 Sep; 16(9):1111-9. PubMed ID: 27267749
[TBL] [Abstract][Full Text] [Related]
38. Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature.
Stork AC; van der Pol WL; Franssen H; Jacobs BC; Notermans NC
J Neurol; 2014 Jul; 261(7):1398-404. PubMed ID: 24781837
[TBL] [Abstract][Full Text] [Related]
39. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
[TBL] [Abstract][Full Text] [Related]
40. Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience.
Matà S; Torricelli S; Barilaro A; Grippo A; Forleo P; Del Mastio M; Sorbi S
J Neurol Sci; 2021 Apr; 423():117335. PubMed ID: 33647732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
